Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers which are identified as having an aberrant activation of the Notch pathway. Such activation has long been implicated in multiple solid tumor and blood-related cancers and has often been associated with more aggressive cancers. Ayala Pharmaceuticals is initially focused on ultra-orphan indications such as salivary gland cancer with an additional focus on larger patient population indications, including triple negative breast cancer as well as an aggressive form of Leukemia.